Issue 2, 2005

A new synthesis of difluoromethanesulfonamides–a novel pharmacophore for carbonic anhydrase inhibition

Abstract

Preparation of the key intermediate carboxydifluoromethanesulfonamide provides direct synthetic access to a wide range of novel difluoromethanesulfonamides, including the acetazolamide analogue (2-ethanoylamino-1,3,4-thiadiazol-5-yl)-difluoromethanesulfonamide. Their water solubility and stability, ether partition coefficient, pKa and submicromolar dissociation constants for human carbonic anhydrase isozyme II (HCA II) make them promising candidates for topical glaucoma therapy.

Graphical abstract: A new synthesis of difluoromethanesulfonamides–a novel pharmacophore for carbonic anhydrase inhibition

Supplementary files

Article information

Article type
Communication
Submitted
02 Nov 2004
Accepted
25 Nov 2004
First published
15 Dec 2004

Org. Biomol. Chem., 2005,3, 222-224

A new synthesis of difluoromethanesulfonamides–a novel pharmacophore for carbonic anhydrase inhibition

N. A. Boyle, W. R. Chegwidden and G. M. Blackburn, Org. Biomol. Chem., 2005, 3, 222 DOI: 10.1039/B416642F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements